【www.zhangdahai.com--公司简介】
【摘要】 目的 了解重组人生长激素(rhGH)在体外对人胃、结肠癌细胞有无促进增殖作用。方法 实验分对照组、rhGH组、奥沙利铂(L-OHP)组和L-OHP+rhGH组,利用体外细胞培养及流式细胞仪等方法,测定不同浓度的rhGH对人胃癌细胞株MKN45、人结肠癌细胞株Colo320细胞周期和增殖指数(PI)的影响。结果 rhGH在体外不促进MKN45和Colo320细胞分裂增殖。rhGH组与对照组、L-OHP+rhGH组与L-OHP组比较均无统计学意义(P>0.05),L-OHP+rhGH组与对照组比较或L-OHP+rhGH组与对应的rhGH组比较,阻滞于G0~G1期的细胞数增加,S期和G2~M期细胞明显减少,PI明显降低(P0.05).The cells arrested in G0~G1 phase obviously increased,meanwhile,the cells in S phase and G2~M phase and PI distinctly decreased compared L-OHP+rhGH group with control group or between L-OHP+rhGH group and rhGH group in comparison(P0.05)。S期:L-OHP组和L-OHP+rhGH组比对照组和rhGH组降低(P0.05),但有升高趋势。G2~M期:L-OHP组和L-OHP+rhGH组比对照组和rhGH组降低(P0.05);同时,L-OHP+rhGH组与对应的rhGH组及对照组比较,G2~M期细胞也减少(P
表2
药物作用后MKN45和Colo320细胞株各组的增殖周期百分数( x±s)
组别
MKN45(%)Colo320(%)
G0~G1SG2~MG0~G1SG2~M
对照组51.5±1.736.2±1.512.3±3.325.6±3.240.1±1.634.2±4.4
L-OHP组81.8±1.5�*8.9±0.7�*9.3±1.257.4±5.4�*25.3±2.8�*17.3±3.4�*
rhGH1组54.6±3.433.5±6.511.9±3.326.4±2.539.9±1.533.6±2.7
rhGH2组53.8±4.134.7±6.111.5±1.625.9±3.741.0±2.234.0±3.4
rhGH3组52.1±4.235.8±7.312.1±3.526.9±3.142.1±2.230.9±2.0
rhGH4组53.9±4.733.9±7.812.2±3.925.4±4.241.9±2.632.7±2.0
L-OHP+rhGH1组82.5±3.4�*7.7±3.8�*9.8±1.957.3±3.0�*26.8±3.1�*15.9±1.1�*
L-OHP+rhGH2组81.2±2.3�*8.6±1.9�*10.2±0.955.7±4.3�*25.8±5.5�*18.5±3.1�*
L-OHP+rhGH3组83.1±1.8�*8.1±5.0�*8.8±4.556.1±7.2�*27.0±5.0�*16.8±4.5�*
L-OHP+rhGH4组82.9±2.9�*7.4±1.6�*9.7±2.456.4±5.2�*26.4±3.6�*17.1±1.1�*
注:与对照组和rhGH各亚组比较,�*P0.05),见表3。
表3
药物作用后MKN45和Colo320细胞株各组
细胞增殖指数( x±s)
组别MKN45(%)Colo320(%)
对照组48.5±1.975.4±3.2
L-OHP组18.2±1.6�*42.6±5.3�*
rhGH1组45.4±4.673.9±2.9
rhGH2组46.2±3.874.1±3.7
rhGH3组47.9±4.273.1±3.1
rhGH4组46.1±5.374.6±4.2
L-OHP+rhGH1组17.5±2.5�*42.7±3.0�*
L-OHP+rhGH2组18.8±2.9�*44.3±4.3
L-OHP+rhGH3组16.9±1.4�*43.9±7.2�*
L-OHP+rhGH4组17.1±2.5�*43.6±5.12�*
注:与对照组和rhGH各亚组比较, �*P0.05),表明rhGH对体外培养的胃、结肠癌细胞无促进增殖的作用。在rhGH与L-OHP合用与对照组和rhGH组比较,S期及G2~M期的细胞及PI明显减少(P0.05)。为临床胃肠道肿瘤患者术后应用rhGH进行代谢调理提供一定参考。由于本实验未对细胞进行同步化处理,所以不能对胃、结肠癌细胞两株细胞株进行比较。
综上所述,本实验提示rhGH在体外不促进人胃、结肠癌细胞的增殖分裂,与以往文献报道结果相似[7-9]。
参 考 文 献
[1] Harrison LE,Blumberg D,Berman R,et al.Effect of human growth hormone on human pancreatic carcinoma growth,protein and cell cycle kinetic.J Surg Res,1996,61(2):317-22.
[2] 陈嘉勇,张捷,谭晶,等.胃、结癌患者术后生长激素应用的价值评估.中国普外基础与临床杂志,1999,6(6):365-367.
[3] Vara-Thorbeck TR,Ruiz-Requena E,Guerrero JA.Effects of human growth hormone on the catabolic state after surgical trauma.Horm Res,1994,45(6):55-60.
[4] 吴力群,杨猛,卢云,等.生长抑素及生长激素瘤内注射治疗大鼠移植性肝肿瘤的研究.中华临床医药杂志,2003,4(6):22-24.
[5] Juergen Tacke,Ulrich Bolder,Armin Herrmann,et al.Long-term risk of gastrointestinal tumor recurrence after postoperative treatment with recombinant human growth hormone.JPEN,2000,24(3):140-144.
[6] Fiebig HH,Dengler W,Hendriks HR.No evidence of tumor growth stimulation in human tumors in vitro following treatment with recombinant human growth hormone.Anticancer Drugs,2000,11(8):659-664.
[7] 郭爱平,李苏宜.重组人生长激素在体外对人胃癌细胞作用的研究.东南大学学报:医学版,2007,26(3):206-209.
[8] Jiayong Chen,Daoming Liang,Ping Gan,et al.In vitro effects of recombinant human growth hormone on growth of human gastric cancer cell line BGC823 cells.World Journal of Gastroenterology,2004,10(8);1132-1136.
[9] 魏寿江,王崇树,王严庆,等.重组人生长激素对体外人结肠癌COLO-320细胞生长的影响.中国普外基础与临床杂志,2003,10(6):572-575.
